Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages. Read more about Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages.
Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs. Read more about Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs.
CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition. Read more about CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition.
Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Read more about Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma.
Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL. Read more about Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL.
PKCd-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia. Read more about PKCd-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia.
KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation. Read more about KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation.
Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia. Read more about Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia.
Differential Gene Expression in KMT2A::AFF1 Leukemia Is Driven By Enhancer Heterogeneity. Read more about Differential Gene Expression in KMT2A::AFF1 Leukemia Is Driven By Enhancer Heterogeneity.
CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?. Read more about CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?.
